Revenue Showdown: Telix Pharmaceuticals Limited vs Alkermes plc

Biopharma Revenue Battle: Alkermes vs. Telix

__timestamp	Alkermes plc	Telix Pharmaceuticals Limited
Wednesday, January 1, 2014	618789000	28336824
Thursday, January 1, 2015	628335000	32319194
Friday, January 1, 2016	745694000	29404631
Sunday, January 1, 2017	903374000	31769230
Monday, January 1, 2018	1094274000	20439380
Tuesday, January 1, 2019	1170947000	24186536
Wednesday, January 1, 2020	1038756000	4680000
Friday, January 1, 2021	1173751000	4898000
Saturday, January 1, 2022	1111795000	155984000
Sunday, January 1, 2023	1663405000	496659000
Monday, January 1, 2024	1557632000

Data in motion

Revenue Showdown: A Tale of Two Biopharma Giants

In the competitive world of biopharmaceuticals, revenue growth is a key indicator of success. Over the past decade, Alkermes plc and Telix Pharmaceuticals Limited have showcased contrasting trajectories. From 2014 to 2023, Alkermes plc consistently outperformed, with revenue peaking at approximately $1.66 billion in 2023, marking a 168% increase from 2014. Meanwhile, Telix Pharmaceuticals, though starting from a modest base, demonstrated impressive growth, especially in recent years. By 2023, Telix's revenue surged to nearly $497 million, a staggering increase of over 1,600% from its 2014 figures. This remarkable growth highlights Telix's rapid ascent in the industry, despite Alkermes' larger revenue base. As these companies continue to innovate, their financial journeys offer valuable insights into the evolving landscape of biopharma.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025